
Cigna (CI) Stock Forecast & Price Target
Cigna (CI) Analyst Ratings
Bulls say
Cigna Group is strategically positioned to leverage the anticipated $100 billion biosimilar market by 2030, underscoring its growth potential within the pharmaceutical landscape. Additionally, the company's recent capability to generate double-digit savings on GLP-1 therapies for employer clients showcases its focus on delivering cost-effective solutions, strengthening its value proposition in the health insurance sector. Furthermore, the expansion of Evernorth is expected to enhance Cigna's resilience against economic downturns, as its end markets demonstrate greater stability, thus supporting the company’s overall financial stability and growth trajectory.
Bears say
Cigna Group faces significant risks that contribute to a negative outlook, including challenges in accurately pricing and managing healthcare costs, which could undermine profitability. Regulatory scrutiny on pharmacy benefit managers (PBMs) is expected to persist longer than anticipated, potentially impacting Cigna’s operational stability and market position. Additionally, slow adoption of biosimilars and specialty drugs, coupled with potential client losses in the Evernorth segment, could further hinder growth prospects and threaten the retention of commercial membership, particularly amid rising unemployment rates.
This aggregate rating is based on analysts' research of Cigna and is not a guaranteed prediction by Public.com or investment advice.
Cigna (CI) Analyst Forecast & Price Prediction
Start investing in Cigna (CI)
Order type
Buy in
Order amount
Est. shares
0 shares